logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
B

Bernadett Szabados

university college london hospitals nhs foundation trust
H指数:24
被引数:3,607

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

FGFR3 Testing in Urothelial Carcinoma: An Expert Commentary on Best Practices From Patient Identification to Result Reporting

尿路上皮癌中的FGFR3检测：从患者识别到结果报告的最佳实践专家评论

European Urology Oncology
IF9.3
2026-09-010
PRE
Comperat, Eva M.; Hartmann, Arndt; Allory, Yves; Bellosillo, Beatriz; Oliveira, Rui Pedro Caetano Moreira; Chiappetta, Caterina; Hodeib, Farah; Hubank, Michael; Klumper, Niklas; Loriot, Yohann; Penault-Llorca, Frederique; Rijken, Astrid; Speel, Ernst-Jan M.; Szabados, Bernadett; Vanden Bempt, Isabelle; Van Leenders, Geert J. L. H.; Vescovo, Mariavittoria; Eckstein, Markus
IUC26600-79 ‘State-of-the-Nation’ Study: Understanding the current NHS treatment pathway to identify opportunities to advance future care of patients with high-risk non-muscle invasive bladder cancer in the UK (SPAN-UK)

IUC26600-79 ‘国情’研究：了解英国当前NHS治疗路径，以识别推进高风险非肌层浸润性膀胱癌患者未来护理的机会（SPAN-UK）

Oncologist
IF4.2
2026-08-210
OAAI
J Aning; J Catto; R Martin; K Chatterton; P Mariappan; S Mccormack; S Gill; B Szabados
ASSOCIATION OF GENOMIC DISEASE BURDEN MARKERS AND PROGRAMMED DEATH-LIGAND 1 WITH CLINICAL OUTCOMES IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER TREATED WITH GEMCITABINE INTRAVESICAL SYSTEM plus CETRELIMAB (CET) OR CET ALONE IN THE PHASE 2 SUNRISE-4 TRIAL

肌肉浸润性膀胱癌患者中基因组疾病负担标志物和程序性死亡配体1与接受吉西他滨膀胱内给药系统联合西特利单抗（CET）或单药西特利单抗治疗的临床结局的相关性：2期SUNRISE-4试验

Journal of Urology
IF6.8
2026-05-010
PRE
Guerrero-Ramos, Felix; Necchi, Andrea; Shore, Neal; Crispen, Paul L.; Szabados, Bernadett; Xylinas, Evanguelos; Urtishak, Karen; Battaglia, Sebastiano; Pinho, Flavia; Hasan, Mohamad; Gong, Cinty; Stitou, Hind; Bhanvadia, Sumeet; Psutka, Sarah P.
Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta-analysis

临床完全缓解作为膀胱癌中病理缓解的替代指标：一项系统评价和荟萃分析

BJU International
IF4.4
2026-03-160
OAAI
Navid Roessler; Marcin Miszczyk; Paolo Gontero; Alessandro Dematteis; Keiichiro Miyajima; Shota Inoue; Katharina Oberneder; Markus von Deimling; Victor M. Schuettfort; Malte W. Vetterlein; Bernadett Szabados; Pawel Rajwa; Pierre I. Karakiewicz; Jeremy Yuen-Chun Teoh; Margit Fisch; Shahrokh F. Shariat
VEGF-TKI Outcomes in Metastatic Renal Cell Carcinoma According to Prior Immune Checkpoint Inhibitor or VEGF-TKI: A Scoping Review and Exploratory Analysis

根据既往免疫检查点抑制剂或VEGF-TKI治疗情况，转移性肾细胞癌中VEGF-TKI的治疗结局：一项范围综述与探索性分析

Cancers
IF4.4
2026-03-020
OAAI
Elizabeth Nally; Agne Jovaisaite; Sara Coca Membribes; Garima Priyadarshini; Catherine Graham; Alan MacDonald; Francesca Jackson-Spence; Bernadett Szabados; Thomas Powles
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial

针对晚期尿路上皮癌的一线治疗方案：比较三周期与六周期铂类化疗后接受阿维鲁zumab维持治疗的疗效——II期DISCUS试验

Annals of Oncology
IF65.4
2025-10-170
OAAI
T. Powles; S.A. Hussain; M.A. Climent; I.G. Carbonero; J. Molina-Cerrillo; J. Puente; P. Borrega; J. Malik; L-M Dourthe; R. Jones; D. Castellano; I. Durán; Y. Loriot; G. Priyadarshini; B. Szabados; F. Jamal; Y.Q. Wang; N. Kotriwala; F. Jackson-Spence; C. Ackerman; E. Grande
CABOSEQ 3-Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab-Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)

CABOSEQ 3-卡博赞替尼与舒尼替尼在一线纳武利尤单抗-伊匹木单抗治疗后的转移性肾细胞癌中的比较：一项使用国际转移性肾细胞癌数据库联盟（IMDC）真实世界数据的靶向试验模拟研究

Clinical Genitourinary Cancer
IF2.7
2025-10-010
OAAI
Lemelin, Audreylie; Maj, David; Takemura, Kosuke; Boyne, Devon J.; Warkentin, Matthew T.; Brenner, Darren R.; Cheung, Winson Y.; Wells, Connor; Labaki, Chris; Mcgregor, Bradley A.; Contreras, Luis Meza; Pal, Sumanta K.; Beuselinck, Benoit; Mckay, Rana R.; Szabados, Bernadett; Powles, Thomas; Yuasa, Takeshi; Ludwig, Lisa; Choueiri, Toni K.; Heng, Daniel Y. C.
On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC

地平线上的视野：关于为BCG-Naïve高危非肌层浸润性膀胱癌患者提供新兴疗法的全球多学科观点

ONCOLOGY AND THERAPY
IF3.2
2025-04-170
OA
Bernadett E. Szabados; Félix Guerrero-Ramos; Enrique Grande; Petros Grivas; Viktor Grünwald; Marta Carpintero Miguel; Syed A. Hussain; Girish S. Kulkarni; Ana Lisa Wilson; Neal D. Shore; Srikala S. Sridhar; Mary Hoyt; Samantha Strumeier; Jennifer Sutton; Julia Brinkmann; Rosemary E. Teresi; Tilman Todenhöfer
Renal cell carcinoma
LANCET
IF88.5
2024-08-018
PRE
Young, Matthew; Jackson-Spence, Francesca; Beltran, Luis; Day, Elizabeth; Suarez, Christina; Bex, Axel; Powles, Thomas; Szabados, Bernadett
Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

在联合免疫疗法时代，转移性肾细胞癌患者接受延期，前期或无细胞减灭性肾切除术的特征: 来自国际转移性肾细胞癌数据库联盟的结果

EUROPEAN UROLOGY ONCOLOGY
IF9.3
2024-06-019
PRE
Takemura, Kosuke; Ernst, Matthew S.; Navani, Vishal; Wells, J. Connor; Bakouny, Ziad; Donskov, Frede; Basappa, Naveen S.; Wood, Lori A.; Meza, Luis; Pal, Sumanta K.; Szabados, Bernadett; Powles, Thomas; Beuselinck, Benoit; Mckay, Rana R.; Lee, Jae-Lyun; Ernst, D. Scott; Kapoor, Anil; Yuasa, Takeshi; Choueiri, Toni K.; Heng, Daniel Y. C.
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer
NATURE COMMUNICATIONS
IF15.7
2024-02-143
OAAI
Rijnders, Maud; Nakauma-Gonzalez, J. Alberto; Robbrecht, Debbie G. J.; Gil-Jimenez, Alberto; Balcioglu, Hayri E.; Oostvogels, Astrid A. M.; Aarts, Maureen J. B.; Boormans, Joost L.; Hamberg, Paul; van der Heijden, Michiel S.; Szabados, Bernadett E.; van Leenders, Geert J. L. H.; Mehra, Niven; Voortman, Jens; Westgeest, Hans M.; de Wit, Ronald; van der Veldt, Astrid A. M.; Debets, Reno; Lolkema, Martijn P.
Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
ANNALS OF ONCOLOGY
IF65.4
2023-11-010
PRE
Takemura, K.; Yuasa, T.; Lemelin, A.; Ferrier, E.; Wells, J. C.; Saad, E.; Saliby, R. M.; Basappa, N. S.; Wood, L. A.; Jude, E.; Pal, S. K.; Donskov, F.; Beuselinck, B.; Szabados, B. E.; Powles, T. B.; Mckay, R. R.; Gebrael, G.; Agarwal, N.; Choueiri, T. K.; Heng, D. Y. C.
Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO plus IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)

一线 (1L) nivolumab + ipilimumab (NIVO + IPI) 治疗转移性肾细胞癌 (mRCC) 后卡博替尼 (CABO) 与舒尼替尼 (SUN) 的比较: 使用国际mRCC数据库联盟 (IMDC) 的真实世界数据进行目标试验仿真

ANNALS OF ONCOLOGY
IF65.4
2023-10-012
PRE
Lemelin, A.; Takemura, K.; Boyne, D. J.; Warkentin, M. T.; Brenner, D. R.; Cheun, W. Y.; Wells, J. C.; Labaki, C.; McGregor, B. A.; Basappa, N. S.; Meza, L. A.; Pal, S. K.; Beuselinck, B.; Mckay, R. R.; Szabados, B. E.; Powles, T. B.; Yuasa, T.; Ludwig, L.; Choueiri, T. K.; Heng, D. Y. C.

研究方向

暂未获取到该数据
T
Thomas Powles
H 指数:77论文数:690被引数:3.6万
M
Michiel S. van der Heijden
H 指数:53论文数:341被引数:2.6万
A
Alain Ravaud
H 指数:80论文数:672被引数:4.4万
A
Aaron Prendergast
H 指数:16论文数:39被引数:2,082
A
Alejo Rodríguez‐Vida
H 指数:32论文数:227被引数:6,016
T
Toni K. Choueiri
H 指数:149论文数:2,478被引数:12.6万
A
Axel Bex
H 指数:66论文数:619被引数:2.4万
C
Cristina Suárez
H 指数:54论文数:376被引数:1.4万
K
Kelly Mousa
H 指数:14论文数:47被引数:2,045
D
Daniel Castellano
H 指数:72论文数:739被引数:4.0万